Drug intelligence / Profile preview

Asset 3

Development stage: Preclinical
Lead developer: Gen1E Lifesciences
Modality: Small Molecules
Administration: Oral

Overview

Asset 3 is an orally bioavailable small molecule inhibitor of ERK1 and ERK2, currently under development by Gen1E Lifesciences for immuno-oncology indications. As a dual inhibitor of the extracellular signal-regulated kinases 1 and 2, it targets the terminal node of the Ras-Raf-MEK-ERK (MAPK) signaling pathway. This pathway is a critical regulator of cell proliferation, differentiation, and survival, and is frequently hyperactivated in various malignancies. By inhibiting ERK1/2, Asset 3 aims to directly suppress tumor growth and potentially modulate the immune response within the tumor microenvironment to enhance anti-cancer activity.

Other names: Gen1E Lifesciences ERK1/2 inhibitorERK1/ERK2 small molecule inhibitor

Targets

MAPK3 (Mitogen-activated protein kinase 1)

Beyond the preview

Go deeper on Asset 3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asset 3.

Explore the full profile